A groundbreaking development in HIV testing has arrived in Canada with the approval of the OraQuick HIV self-test, a simple oral swab kit that provides results in as little as 20 minutes. Announced by OraSure Technologies on Tuesday, this test marks a significant advancement in HIV self-diagnosis, as it is the first of its kind in the country that does not require a blood sample. The introduction of this test is seen as a crucial step towards Canada’s ambitious goal of eliminating HIV as a public health threat by 2030.
A Less Invasive Testing Option
Unlike traditional tests that necessitate blood draws, the OraQuick self-test employs an oral swab resembling a popsicle stick, designed to be swabbed along the gums. This less invasive approach could help alleviate discomfort for those who are squeamish about needles or blood, potentially encouraging more individuals to get tested. Dr. Sean Rourke, a scientist at the MAP Centre for Urban Health Solutions at St. Michael’s Hospital and the exclusive distributor of the test in Canada, expressed optimism about the test’s potential impact. “This is the gap that we’ve been missing to reach the people who need it the most,” he stated, underlining the importance of making testing accessible to high-risk communities.
The urgency surrounding HIV testing is underscored by recent statistics, indicating a troubling rise in new HIV diagnoses in Canada. The number of diagnoses surged from 1,800 in 2022 to 2,434 in 2023, before slightly declining to 1,826 in 2024. Alarmingly, provinces like Manitoba and Saskatchewan report new diagnosis rates that are three to four times higher than the national average.
Community Engagement Essential for Success
Dr. Rourke emphasised that achieving the 2030 elimination goal hinges on governmental support for community-based organisations that can distribute the test at no cost. His team plans to start taking orders soon from health providers and frontline agencies, aiming to reach those most at risk due to health inequities, including African, Caribbean, and Black communities, as well as Indigenous Peoples and men who have sex with men.
To ensure the test’s efficacy and acceptance, Rourke’s team has collaborated with various community organisations over the past five years. They conducted clinical trials that reached 100,000 individuals affected by HIV, creating a network of agencies that can effectively engage with those who may not seek help through traditional health systems.
Addressing Mistrust and Cultural Sensitivity
Community outreach is vital in building trust, particularly among populations that have historically been hesitant to engage with health research due to past experiences. Nonty Nkala, a research and outreach coordinator with Women’s Health in Women’s Hands in Toronto, highlighted the importance of community involvement in this process. “When research is being done by fellow Black people, and it’s being led by Black people, there’s a level of trust there,” she explained.
Nkala noted that providing self-tests through community events, such as churches and festivals, has been instrumental in addressing apprehension and fostering a supportive environment for those considering testing. The stigma surrounding HIV remains a challenge, particularly for newcomers to Canada, who may feel uncomfortable discussing the topic.
The Future of HIV Testing in Canada
While the oral fluid HIV self-test has been a success in the U.S. since its approval in 2012 and is recommended by the World Health Organization, its introduction in Canada has been delayed. Dr. Rourke pointed out that suppliers needed evidence of market demand, and Health Canada required assurance that the test met their standards.
The Canadian government has previously invested in finger prick HIV self-tests, committing $8 million in 2022, but Rourke expressed concern over the lack of federal funding to support the distribution of the new oral test. Some provinces, such as Saskatchewan and Nova Scotia, have stepped in to launch their own HIV self-testing programmes, but national coordination will be crucial for widespread success.
The oral test is expected to retail for between £15 and £20, a price point that could facilitate greater access compared to existing blood tests, which can cost around £35 online.
Why it Matters
The arrival of the OraQuick HIV self-test in Canada represents a transformative opportunity to enhance access to HIV testing, particularly for vulnerable populations. By lowering barriers to testing and addressing community-specific needs, Canada could take significant strides towards its goal of eliminating HIV as a public health concern by 2030. The potential for increased awareness and early detection could ultimately save lives and change the narrative around HIV in the country.
